Successful management of infusion reaction accompanying the start of cetuximab therapy

Supportive Care in Cancer

Volumn 15, Issue 4, 2007, Pages 445-449

  Melichar, Bohuslav ^a   Cerman Jr , Jaroslav ^a   Malířová, Eva ^a  

^a UNIVERSITY HOSPITAL HRADEC KRALOVE   (Czech Republic)

Author keywords

Cetuximab; Colorectal carcinoma; Infusion reaction; Intensive care

Indexed keywords

CALCIUM; CETUXIMAB; DEXAMETHASONE; DITHIADEN; EPOTHILONE B; FLUOROURACIL; FOLINIC ACID; HYDROCORTISONE; IRINOTECAN; OXALIPLATIN;

ADULT; AGED; ARTICLE; CASE REPORT; COLON ADENOCARCINOMA; CONSCIOUSNESS DISORDER; DISEASE SEVERITY; DRUG INFUSION; HUMAN; INJECTION SITE ERYTHEMA; INJECTION SITE REACTION; INTENSIVE CARE UNIT; LOADING DRUG DOSE; MALE; PATIENT MONITORING; PATIENT TRANSPORT; PRIORITY JOURNAL; STRIDOR; THERAPY EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE; TRISMUS; VITAL SIGN;

ADENOCARCINOMA; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; DEXAMETHASONE; DRUG HYPERSENSITIVITY; GLUCOCORTICOIDS; HUMANS; INFUSION PUMPS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; SIGMOID NEOPLASMS;

EID: 34247868234     PISSN: 09414355     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00520-006-0159-x     Document Type: Article

References (10)

1. Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, Jones CU, Sur R, Raben D, Jassem J, Ove R, Kies MS, Baselga J, Youssoufian H, Amellal N, Rowinsky EK, Ang KK (2006) Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354:567-578
2. Byrd JC, Waselenko JK, Maneatis TJ, Murphy T, Ward FT, Monahan BP, Sipe MA, Donegan S, White CA (1999) Rituximab therapy in hematologic malignancy patients with circulating blood tumor cells: association with increased infusion-related side effects and rapid blood tumor clearance. J Clin Oncol 17:791-795
3. Cheifetz A, Smedley M, Martin S, Reiter M, Leone G, Mayer L, Plevy S (2003) The incidence and management of infusion reactions to infliximab: a large center experience. Am J Gastroenterol 98:1315-1324
4. Cunningham D, Hurnblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype C, Chau I, Van Cutsem E (2004) Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351:337-345
5. Dillman RO (1999) Infusion reactions associated with the therapeutic use of monoclonal antibodies in the treatment of malignancy. Cancer Metastasis Rev 18:465-471
6. Iannello A, Ahmad A (2005) Role of antibody-dependent cell-mediated cytotoxicity in the efficacy of therapeutic anti-cancer monoclonal antibodies. Cancer Metastasis Rev 24:487-499
7. Puchner TC, Kugathasan S, Kelly KJ, Binion DG (2001) Successful desensitization and therapeutic use of infliximab in adult and pediatric Crohn's disease patients with prior anaphylactic reaction. Inflamm Bowel Dis 7:34-37
8. Saltz LB, Meropol NJ, Loehrer PJ, Needle MN, Kopit J, Mayer RJ (2004) Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 22:1201-1208
9. Shin DM, Donato NJ, Perez-Soler R, Shin HJC, Wu JY, Zhang P, Lawhorn K, Khuri FR, Glisson BS, Myers J, Clayman G, Pfister D, Falcey J, Waksal H, Mendelson J, Hong WK (2001) Epidermal growth factor receptor-targeted therapy with C225 and cisplatin in patients with head and neck cancer. Clin Cancer Res 7:1204-1213
10. van der Kolk LE, Grillo-Lopez AJ, Baars JW, Hack CE, van Oers MHJ (2001) Complement activation plays a key role in the side-effects of rituximab treatment. Br J Haematol 115:807-811